$INTS News

HC Wainwright & Co. Maintains Buy on Intensity Therapeutics, Raises Price Target to $7

Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary

Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Intensity Therapeutics Q2 EPS $(1.11), Inline

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Intensity Therapeutics Administers New Patients With INT230‑6 In INVINCIBLE‑4 Switzerland Study; Trial Evaluates pCR Rates Vs Null Hypothesis Across SOC And INT230‑6+SOC Cohorts

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Intensity Therapeutics (NASDAQ:INTS) Q1 2026 Results Show EPS Beat Despite No Revenue

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Q1 EPS $(0.96) Beats $(1.11) Estimate

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Q4 EPS $(1.31) Misses $(0.04) Estimate